is sitagliptin a glp-1 Glucagon-like peptide-1 GLP-1-RA and DPP-4 inhibitors in
Description
However, on the basis of the evidence presented above, we find this explanation insufficient to account uniformly for the suppressed water intake in the present studies
Agilent Feature Extraction software (version 11.0.1.1) was used to analyze acquired array images
Results over a 36-month duration revealed that Ozempic or Wegovy users experienced substantially elevated risks of developing NAION in comparison to those on non-semaglutide medications
Kalscheuer H, Seufert J, Lanzinger S et al (2019) Event rates and risk factors for the development of diabetic ketoacidosis in adult patients with type 1 diabetes: analysis from the DPV registry based on 46,966 patients
Enhanced synaptic plasticity in newly generated granule cells of the adult hippocampus
